---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-014296"
form_type: "8-K"
ticker: "FBLG"
cik: "0001958777"
company_name: "FibroBiologics, Inc."
filed_at: "2025-06-09T23:59:59+00:00"
generated_at: "2026-05-19T17:35:26.526665+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# FibroBiologics appoints Jason D. Davis, CPA, as CFO; base salary $350k

## Summary
- Jason D. Davis appointed CFO effective June 9, 2025; previously CFO at Virax Biolabs, led IPO in July 2022.
- Employment agreement includes base salary of $350k, annual bonus up to 40% of base, and sign-on cash bonus of $15k.
- Received option grant of 450,000 shares under 2022 Stock Plan; vests 1/4 on first anniversary, then monthly.
- Davis has 20+ years finance experience; at HyperDynamics increased market cap from $20M to $700M and raised $200M+.
- Appointment comes as FibroBiologics advances toward Phase 1/2 clinical trial for diabetic foot ulcers in H2 2025.

## SEC filing metadata
- accession: 0001641172-25-014296
- form_type: 8-K
- ticker: FBLG
- cik: 0001958777
- company_name: FibroBiologics, Inc.
- filed_at: 2025-06-09T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1958777/000164117225014296/0001641172-25-014296-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1958777/000164117225014296/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-014296
- JSON: https://secwatch.observer/filing/0001641172-25-014296.json
- Plain text: https://secwatch.observer/filing/0001641172-25-014296.txt

## Key facts
- Executive change
  Jason D. Davis was appointed as Chief Financial Officer at FibroBiologics, Inc..
  - Action: appointed
  - Role: Chief Financial Officer
  source text: On June 9, 2025, FibroBiologics, Inc. (the “Company”) announced that Jason D. Davis has been appointed as the Company’s Chief Financial Officer, effective as of June 9, 2025 (the “Effective Date”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1958777/000164117225014296/0001641172-25-014296-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.